Literature DB >> 32883169

The role of concomitant cardiovascular diseases and cardiac biomarkers for predicting mortality in critical COVID-19 patients.

Nesim Aladağ1, Rukiye Derin Atabey2.   

Abstract

BACKGROUND: to identify the potential cardiovascular risk factors associated with mortality in hospitalised COVID-19 patients.
METHODS: All consecutive patients admitted to intensive care unit (ICU) of our institute for COVID-19 from 1 April 2020 to 20 May 2020 were included. Patient characteristics including complete medical history and comorbid diseases, admission and 7th day blood test results and clinical characteristics were compared between survivors and non-survivors.
RESULTS: There were no significant difference between survivors and non-survivors regarding age, gender, and pre-existing coronary artery disease, hypertension, diabetes, heart failure, coronary artery bypass grafting surgery, percutaneous coronary intervention and coronary stenting. Admission D-dimer and NT-proBNP levels of non-survivors were significantly higher than survivors. CRP, procalcitonin, creatine kinase (CK) and troponin I levels on 7th day of admission were significantly higher in non-survivors compared to survivors. In addition, both admission and 7th day lymphocyte count were lower in non-survivors compared to that of the survivors. CRP declined from admission to 7th day of hospitalisation in survivors, whereas a median 6.75 mg/L increase was observed in non survivors. The peak and minimum CRP, procalcitonin and levels were significantly higher in non-survivors than survivors. The peak NT-proBNP level of non-survivors was also significantly higher than that of the survivors. Intubation, lower GFR values and higher NT-proBNP values were predictive for death.
CONCLUSION: The prothrombotic coagulopathy mediated by the endothelial interaction with SARS-CoV-2 may also have role in unfavourable prognosis in COVID-19. These readily available biomarkers might be useful in risk stratification of COVID-19 cases.

Entities:  

Keywords:  COVID-19; biomarker; cardiac injury; cardiovascular disease

Mesh:

Substances:

Year:  2020        PMID: 32883169     DOI: 10.1080/00015385.2020.1810914

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  9 in total

1.  Cardiac biomarkers and COVID-19: A systematic review and meta-analysis.

Authors:  Wen An; Ju-Seop Kang; Qiuyang Wang; Tae-Eun Kim
Journal:  J Infect Public Health       Date:  2021-07-29       Impact factor: 7.537

2.  Prognostic significance of CHADS2 and CHA2DS2-VASc scores to predict unfavorable outcomes in hospitalized patients with COVID-19.

Authors:  Mahnaz Montazeri; Mohammad Keykhaei; Sina Rashedi; Shahrokh Karbalai Saleh; Marzieh Pazoki; Azar Hadadi; Seyyed Hamidreza Sharifnia; Mehran Sotoodehnia; Sanaz Ajloo; Samira Kafan; Haleh Ashraf
Journal:  J Cardiovasc Thorac Res       Date:  2022-03-14

3.  The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis.

Authors:  Jiali Long; Yefei Luo; Yuehong Wei; Chaojun Xie; Jun Yuan
Journal:  Am J Emerg Med       Date:  2021-04-20       Impact factor: 4.093

Review 4.  Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity.

Authors:  Muhammad Manjurul Karim; Shahnaz Sultana; Rokaia Sultana; Mohammad Tariqur Rahman
Journal:  J Infect Public Health       Date:  2021-10-04       Impact factor: 3.718

5.  Impact of the COVID-19 Pandemic on Patients Without COVID-19 With Acute Myocardial Infarction and Heart Failure.

Authors:  Daniel K Fox; R J Waken; Daniel Y Johnson; Gmerice Hammond; Jonathan Yu; Erika Fanous; Thomas M Maddox; Karen E Joynt Maddox
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

6.  A Hybrid Feature Selection Approach to Screen a Novel Set of Blood Biomarkers for Early COVID-19 Mortality Prediction.

Authors:  Asif Hassan Syed; Tabrej Khan; Nashwan Alromema
Journal:  Diagnostics (Basel)       Date:  2022-06-30

7.  Describing characteristics of adults with and without congenital heart defects hospitalized with COVID-19.

Authors:  Perla Diaz; Will Coughlin; Wilson Lam; Peter Ermis; David Aguilar; Cecilia M Ganduglia Cazaban; A J Agopian
Journal:  Birth Defects Res       Date:  2022-06-11       Impact factor: 2.661

8.  B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.

Authors:  Angelo Zinellu; Salvatore Sotgia; Ciriaco Carru; Arduino A Mangoni
Journal:  Front Cardiovasc Med       Date:  2021-06-24

Review 9.  Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.

Authors:  Angelo Zinellu; Salvatore Sotgia; Alessandro G Fois; Arduino A Mangoni
Journal:  Adv Med Sci       Date:  2021-07-07       Impact factor: 3.287

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.